| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1046/J.1365-2036.2001.00925.X |
| P698 | PubMed publication ID | 11207504 |
| P2093 | author name string | Camilleri M | |
| P2860 | cites work | Integrated modelling of the clinical pharmacokinetics of SDZ HTF 919, a novel selective 5-HT4 receptor agonist, following oral and intravenous administration | Q33420644 |
| Review article: roles played by 5-hydroxytryptamine in the physiology of the bowel | Q33701260 | ||
| Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial | Q33896354 | ||
| Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials | Q33969643 | ||
| U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact | Q34353536 | ||
| The irritable bowel syndrome: mechanisms and a practical approach to management | Q36110388 | ||
| Review article: irritable bowel syndrome | Q41356171 | ||
| Irritable bowel syndrome: a technical review for practice guideline development | Q41493711 | ||
| Characterization of the 5-HT receptor potentiating neuromuscular cholinergic transmission in strips of human isolated detrusor muscle | Q41808678 | ||
| Pharmacological analysis of 5-hydroxytryptamine effects on electrically stimulated human isolated urinary bladder | Q41972956 | ||
| 5-Hydroxytryptamine4 receptor agonists initiate the peristaltic reflex in human, rat, and guinea pig intestine | Q45112735 | ||
| Serotonergic regulation of adrenocortical function | Q47726229 | ||
| High affinity of SDZ HTF-919 related molecules for calf and human caudate 5-HT4 receptors | Q48294612 | ||
| Psychometric scores and persistence of irritable bowel after infectious diarrhoea. | Q51117034 | ||
| Effect of meal timing not critical for the pharmacokinetics of tegaserod (HTF 919). | Q51561302 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | review article | Q7318358 |
| P304 | page(s) | 277-289 | |
| P577 | publication date | 2001-03-01 | |
| P1433 | published in | Alimentary Pharmacology & Therapeutics | Q4726656 |
| P1476 | title | Review article: tegaserod | |
| P478 | volume | 15 |
| Q46721499 | 5-Hydroxytryptamine effects in the gut: the 3, 4, and 7 receptors |
| Q35124506 | A clinical approach to constipation |
| Q36168378 | A small molecule screening to detect potential therapeutic targets in human podocytes |
| Q46863112 | Activation of peripheral 5-HT receptors attenuates colonic sensitivity to intraluminal distension |
| Q34966570 | Acupuncture for visceral pain: neural substrates and potential mechanisms |
| Q28280057 | Acute colonic pseudoobstruction |
| Q37357185 | Antispasmodic effects of yarrow (Achillea millefolium L.) extract in the isolated ileum of rat. |
| Q35683216 | Benefit-risk assessment of tegaserod in irritable bowel syndrome |
| Q50019963 | Cardiovascular safety of prokinetic agents: A focus on drug-induced arrhythmias. |
| Q57480824 | Chapter 26. To market, to market - 2001 |
| Q36687444 | Contribution of gender to pathophysiology and clinical presentation of IBS: should management be different in women? |
| Q40498391 | Delayed Gastric Emptying in Functional Dyspepsia |
| Q44914306 | Desensitization of the peristaltic reflex induced by mucosal stimulation with the selective 5-HT4 agonist tegaserod |
| Q35176981 | Diagnosis and treatment of chronic gastroparesis and chronic intestinal pseudo-obstruction. |
| Q51491947 | Double-blind, randomized, placebo-controlled study to evaluate the effects of tegaserod on gastric motor, sensory and myoelectric function in healthy volunteers. |
| Q36478089 | Drugs acting on serotonin receptors for the treatment of functional GI disorders |
| Q37570550 | Emerging drugs for chronic constipation |
| Q36458417 | Emerging drugs for irritable bowel syndrome |
| Q35216829 | Evaluation of drug treatment in irritable bowel syndrome |
| Q46613363 | Expression and function of 5-HT4 receptors in the mouse enteric nervous system |
| Q43906144 | Functional (Nonulcer) Dyspepsia |
| Q30433078 | Functional GI disorders: from animal models to drug development |
| Q34579697 | Gastric emptying in diabetes: clinical significance and treatment. |
| Q35190650 | Gastric function measurements in drug development |
| Q34430659 | Gastrointestinal afferents as targets of novel drugs for the treatment of functional bowel disorders and visceral pain |
| Q36874377 | Importance of 5-hydroxytryptamine receptors on intestinal afferents in the regulation of visceral sensitivity |
| Q34150284 | Irritable bowel syndrome: a little understood organic bowel disease? |
| Q35176961 | Irritable bowel syndrome: evaluation and treatment |
| Q45929234 | Lack of association of tegaserod with adverse cardiovascular outcomes in a matched case-control study. |
| Q33425798 | Long-term safety of tegaserod in patients with constipation-predominant irritable bowel syndrome |
| Q26862565 | Main ion channels and receptors associated with visceral hypersensitivity in irritable bowel syndrome |
| Q37275958 | Management of chronic constipation in the elderly |
| Q28206145 | Molecular, pharmacological and functional diversity of 5-HT receptors |
| Q35178783 | New approaches to the medical treatment of irritable bowel syndrome |
| Q34848280 | New developments in the diagnosis and treatment of irritable bowel syndrome |
| Q35100294 | New developments in the treatment of functional dyspepsia |
| Q35094684 | Novel therapies in the treatment of irritable bowel syndrome |
| Q46552857 | Omeprazole delays gastric emptying in healthy volunteers: an effect prevented by tegaserod |
| Q34479610 | Pathophysiology and management of irritable bowel syndrome |
| Q35124253 | Pharmacologic therapy for the irritable bowel syndrome |
| Q35596862 | Pharmacology of serotonin: what a clinician should know. |
| Q35176998 | Pharmacotherapy for intestinal motor and sensory disorders |
| Q44858988 | Regional gastric contractility alterations in a diabetic gastroparesis mouse model: effects of cholinergic and serotoninergic stimulation |
| Q34650033 | Review article: serotonin receptors and transporters -- roles in normal and abnormal gastrointestinal motility |
| Q34421482 | Review article: the pharmacological treatment of acute colonic pseudo-obstruction |
| Q35925555 | Review of tegaserod in the treatment of irritable bowel syndrome |
| Q35047066 | Role of serotonin in the pathophysiology of the irritable bowel syndrome |
| Q33425261 | Safety and tolerability of tegaserod in patients with irritable bowel syndrome and diarrhea symptoms |
| Q33431808 | Safety profile of tegaserod, a 5-HT4 receptor agonist, for the treatment of irritable bowel syndrome |
| Q36931162 | Sensory signalling effects of tegaserod in patients with irritable bowel syndrome with constipation |
| Q74404032 | Serotonergic Agents in the Treatment of Functional Gastrointestinal Disorders |
| Q34699859 | Serotonergic modulation of visceral sensation: lower gut. |
| Q37132811 | Serotonin pharmacology in the gastrointestinal tract: a review |
| Q36822923 | Serotonin receptor modulators in the treatment of irritable bowel syndrome. |
| Q38178543 | Serotonin receptors and their role in the pathophysiology and therapy of irritable bowel syndrome |
| Q34106497 | Serotoninergic neuroenteric modulators |
| Q27314604 | Simultaneous optical and electrical in vivo analysis of the enteric nervous system |
| Q34394157 | Symptomatic efficacy of beidellitic montmorillonite in irritable bowel syndrome: a randomized, controlled trial |
| Q33991247 | Systematic review: acute colonic pseudo-obstruction |
| Q35675791 | Systematic review: incidence of abdominal/pelvic surgery amongst patients using tegaserod in randomized controlled trials |
| Q43267055 | Tegaserod in the treatment of irritable bowel syndrome with constipation |
| Q35208550 | Tegaserod maleate in the treatment of irritable bowel syndrome: a clinical review |
| Q44352722 | Tegaserod, a 5-HT4 receptor partial agonist, decreases sensitivity to rectal distension in healthy subjects |
| Q44882308 | Tegaserod--merely a laxative? |
| Q34768534 | Tegaserod: a new 5-HT(4) agonist in the treatment of irritable bowel syndrome |
| Q46604896 | Tegaserod: long-term treatment for irritable bowel syndrome patients with constipation in primary care |
| Q24671423 | The 5-HT4 receptor agonist, tegaserod, is a potent 5-HT2B receptor antagonist in vitro and in vivo |
| Q37280260 | The Brain-Gut Axis in Abdominal Pain Syndromes |
| Q35025872 | The Pharmacology of TD-8954, a Potent and Selective 5-HT(4) Receptor Agonist with Gastrointestinal Prokinetic Properties |
| Q34446583 | The effect of fluoxetine in patients with pain and constipation-predominant irritable bowel syndrome: a double-blind randomized-controlled study |
| Q46757034 | The effect of tegaserod on esophageal submucosal glands bicarbonate and mucin secretion |
| Q34770217 | The in vitro pharmacological profile of TD-5108, a selective 5-HT(4) receptor agonist with high intrinsic activity |
| Q84912353 | The inability of tegaserod to affect platelet aggregation and coronary artery tone at supratherapeutic concentrations |
| Q78741758 | The irritable bowel syndrome |
| Q43309782 | The mechanism of enhanced defecation caused by the ghrelin receptor agonist, ulimorelin |
| Q35071310 | The role of experimental models in developing new treatments for irritable bowel syndrome |
| Q35956617 | The treatment of chronic constipation in elderly people: an update |
| Q74707172 | Treatment Options for Refractory Childhood Constipation |
| Q61960606 | Treatment of irritable bowel syndrome |
| Q40292644 | Treatment options for chronic abdominal pain in children and adolescents |
| Q43235987 | Upper gastrointestinal promotility drugs: not all uniform? |
Search more.